Being diagnosed with severe mental health disease means that you see your doctor few times a year for an interview that always start with "How have you been for the last 2-3 months? Anything in particular?" How much would you remember to tell your doctor so he/she could adjust your treatment?
Therefore, the doctor decision is based on the experience to ask and the patient ability to describe. And because it is not always optimal, patient experiences relapse from bipolar disorder or schizophrenia on average every 2 years. This also often leads to lengthy hospitalization.
Globally, there are more than
70 million peoplesuffering from bipolar disorder or schizophrenia.
Patient with bipolar disorder or schizophrenia is onboarded by his/her psychiatrist. System starts to log-in information about the movement that allows for further calculation. Also, the patient is asked to fill in the mood questionnaire on weekly basis to calibrate the monitoring algorithm.
On a continuous basis the doctor, medical staff or in some cases family members can see the data collected by the system and manually entered by the patient (medication changes, key events). Algorithms applied to the data allows the doctor to see the additional information (i.e. digital phenotypes, clinical clusters etc.) which allows a more efficient treatment.
Doctor´s decision support & patient´s empowerment system in place informs the doctor/ medical staff in case there is an increased probability of disease relapse in order to do an early intervention. Based on literature evidence, early intervention shortens the length of hospitalization and can avoid the hospitalization altogether.
Although focus recently is often on general depression, schizophrenia and bipolar disorder are here for long time. These diagnoses are better understood and clear focus in the huge complexity of the brain helps to apply structured math.
Key opinion leaders in European and US psychiatry support the long-term monitoring of mental health patient as the only way to understand the diseases better. Mindpax is unique in collecting highly annotated clinical data in clinical trials (often being the largest and longest with such focus).
Mindpax CMO Dr. Filip Spaniel, author of the first long-term monitoring and relapse prediction system for schizophrenia ITAREPS. Mindpax is supported by European psychiatric key opinion leaders.
You will usually receive one newsletter per month with all the important updates, our progress and interesting articles. Follow our journey with us.